| Alternative Names | CD126,IL-6R-1,IL-6RA,IL6RA,IL-6R-alpha,IL6RQ,gp80 |
| Source | Human IL-6RA Protein; hFc Tag (GM-88766RP) is expressed from human 293 cells (HEK-293). It contains AA Leu 20 - Pro 365 (Accession # NP_000556.1). This protein carries a hFc tag at the C-terminus. |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/μg, determined by LAL gel clotting assay |
| Predicted Mol Mass | 64.5 kDa |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Description | IL-6RA protein, full name Interleukin-6 Receptor Subunit Alpha, also known as CD126, IL-6Rα, or gp80, is an important cell surface transmembrane glycoprotein and a member of the type I cytokine receptor family. IL-6RA protein plays a crucial role in regulating immune responses, hematopoiesis, and acute-phase inflammatory reactions by binding to its ligand interleukin-6 (IL-6) with high affinity, thereby forming a complex with gp130 (IL-6ST) and activating downstream JAK/STAT3, MAPK, and PI3K/Akt signaling pathways in normal physiological conditions. Currently, IL-6RA-targeted therapeutic strategies have demonstrated significant clinical efficacy, with the humanized monoclonal antibody Tocilizumab (Actemra®) being approved for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, Castleman's disease, and severe cytokine release syndrome (CRS) associated with CAR-T therapy. In summary, IL-6RA protein plays a pivotal role in inflammation, autoimmunity, and tumorigenesis, and holds great significance for understanding immunopathology, identifying novel therapeutic targets, developing anti-cytokine biologics and combination immunotherapies, and evaluating patient prognosis in chronic inflammatory diseases and malignancies. |
| Alternative Names | CD126,IL-6R-1,IL-6RA,IL6RA,IL-6R-alpha,IL6RQ,gp80 |
| Source | Human IL-6RA Protein; hFc Tag (GM-88766RP) is expressed from human 293 cells (HEK-293). It contains AA Leu 20 - Pro 365 (Accession # NP_000556.1). This protein carries a hFc tag at the C-terminus. |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/μg, determined by LAL gel clotting assay |
| Predicted Mol Mass | 64.5 kDa |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Description | IL-6RA protein, full name Interleukin-6 Receptor Subunit Alpha, also known as CD126, IL-6Rα, or gp80, is an important cell surface transmembrane glycoprotein and a member of the type I cytokine receptor family. IL-6RA protein plays a crucial role in regulating immune responses, hematopoiesis, and acute-phase inflammatory reactions by binding to its ligand interleukin-6 (IL-6) with high affinity, thereby forming a complex with gp130 (IL-6ST) and activating downstream JAK/STAT3, MAPK, and PI3K/Akt signaling pathways in normal physiological conditions. Currently, IL-6RA-targeted therapeutic strategies have demonstrated significant clinical efficacy, with the humanized monoclonal antibody Tocilizumab (Actemra®) being approved for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, Castleman's disease, and severe cytokine release syndrome (CRS) associated with CAR-T therapy. In summary, IL-6RA protein plays a pivotal role in inflammation, autoimmunity, and tumorigenesis, and holds great significance for understanding immunopathology, identifying novel therapeutic targets, developing anti-cytokine biologics and combination immunotherapies, and evaluating patient prognosis in chronic inflammatory diseases and malignancies. |
